Current strategies toward safer mu opioid receptor drugs for pain management

Expert Opinion on Therapeutic Targets
Aliza T EhrlichEmmanuel Darcq

Abstract

Pain relief remains a major public health challenge. The most efficient available painkillers are opioids targeting the mu opioid receptor (MOR). MORs are expressed in the areas of the brain [including pain and respiratory centers] that are important for processing reward and aversion. Thus, MOR activation efficiently alleviates severe pain, but the concomitant reward and respiratory depressant effects pose a threat; patients taking opioids potentially develop opioid addiction and high risk for overdose. Areas covered: Ongoing efforts to generate safer opioid analgesics are reviewed here. The design of biased compounds that trigger MOR induced G protein over β-arrestin signaling, peripheral opioids, drugs targeting MORs in heteromers and drugs enhancing endogenous opioid activity are discussed. Expert opinion: There is evidence that throttling MOR signaling may lead to an era of opioids that are truly efficient painkillers with lower side effects and risk of overdose. However, few of the drugs derived from the advanced approaches outlined here, are getting approval by regulatory committees for use in clinical settings. Thus, there is an urgent need to (i) better clarify mechanisms underlying the hazardous physiological effects ...Continue Reading

References

Jan 1, 1989·Annual Review of Psychology·R A Wise, P P Rompre
May 1, 1988·Journal of Ethnopharmacology·K L Jansen, C J Prast
May 1, 1983·Journal of Ethnopharmacology·L J ValdésA G Paul
Aug 9, 1996·The Journal of Biological Chemistry·D E KeithM von Zastrow
Apr 2, 1999·Trends in Pharmacological Sciences·B L Kieffer
Jul 22, 2005·Journal of Medicinal Chemistry·Wayne W HardingThomas E Prisinzano
Dec 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·David J DanielsPhilip S Portoghese
Jan 18, 2007·Expert Opinion on Therapeutic Targets·Florence Noble, Bernard P Roques
Jul 3, 2008·The Journal of Pharmacology and Experimental Therapeutics·Eduardo R ButelmanMary Jeanne Kreek
Oct 20, 2009·Cell·Allan I BasbaumDavid Julius
Oct 28, 2010·Expert Opinion on Pharmacotherapy·Brian DurkinPeter Glass
Oct 5, 2011·Pharmacological Reviews·Christoph Stein, Halina Machelska
Oct 6, 2011·Nature Reviews. Neuroscience·Aldo BadianiYavin Shaham
Oct 25, 2011·Anesthesiology·Ream Al-Hasani, Michael R Bruchas
Mar 23, 2012·Nature·Aashish ManglikSébastien Granier
Mar 31, 2012·Nature Reviews. Drug Discovery·Bernard P RoquesMichel Wurm
Jun 20, 2012·British Journal of Pharmacology·Amynah A PradhanChristopher J Evans
Jan 10, 2013·The Journal of Pharmacology and Experimental Therapeutics·Scott M DeWireJonathan D Violin
Jan 17, 2013·Pharmacological Reviews·John T WilliamsMacdonald J Christie
Jun 12, 2013·Proceedings of the National Academy of Sciences of the United States of America·Neil T BurfordAndrew Alt
Jun 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Eyup AkgünPhilip S Portoghese
Jul 3, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ivone GomesLakshmi A Devi
Sep 27, 2013·Frontiers in Pharmacology·Christoph Stein
Feb 28, 2014·British Journal of Pharmacology·Wakako FujitaLakshmi A Devi
Mar 14, 2014·Brain Structure & Function·Eric ErbsDominique Massotte
Mar 29, 2014·British Journal of Pharmacology·D Massotte
Jul 4, 2015·Molecular Pharmacology·Terry Kenakin
Sep 4, 2015·Annual Review of Medicine·Christoph Stein
Oct 31, 2015·Annual Review of Pharmacology and Toxicology·Ivone GomesLakshmi A Devi
Jun 9, 2016·Expert Opinion on Pharmacotherapy·Emidio ScarpelliniAntonio Gasbarrini
Jun 12, 2016·Biochemical Pharmacology·Georgina L ThompsonMeritxell Canals
Aug 18, 2016·Nature·Aashish ManglikBrian K Shoichet
Aug 18, 2016·Nature·Brigitte L Kieffer
Aug 31, 2016·Proceedings of the National Academy of Sciences of the United States of America·Huiping DingMei-Chuan Ko

❮ Previous
Next ❯

Citations

Jan 11, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jérémie NeastaSami Ben Hamida
Mar 14, 2020·Behavioural Pharmacology·Vicente Martínez, Raquel Abalo
Feb 23, 2020·Military Medicine·Zygmunt F DembekAiguo Wu
Jun 27, 2019·Pharmaceuticals·Daria A BelinskaiaNatalia N Shestakova
Jun 1, 2020·Molecular Pharmacology·Farhana SaklothVenetia Zachariou
Jan 19, 2021·Pain Management·Sarada S Eleswarpu, Ashraf S Habib
Jan 31, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Michael VoronkovLevon Isakulyan
Nov 15, 2020·International Journal of Molecular Sciences·Damian BartuziDariusz Matosiuk
Mar 12, 2021·Current Pain and Headache Reports·Sumanth KuppalliMark R Jones
May 11, 2021·Current Pain and Headache Reports·Raghav SethAmitabh Gulati
Mar 19, 2021·Chemistry : a European Journal·Carlotta BorgarelliErmal Ismalaj
May 31, 2021·Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society for Photobiology·Igor Rafael Correia Rocha, Marucia Chacur
Aug 10, 2021·Expert Opinion on Drug Safety·Hon Sen Tan, Ashraf S Habib
Apr 8, 2020·ACS Pharmacology & Translational Science·Md Taufiq NasseefEmmanuel Darcq

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.